Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.84

Margin Of Safety %

Put/Call OI Ratio

0.77

EPS Next Q Diff

0.01

EPS Last/This Y

-0.02

EPS This/Next Y

1.16

Price

72.46

Target Price

89.53

Analyst Recom

1.06

Performance Q

-5.4

Relative Volume

1

Beta

1.11

Ticker: INSM




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19INSM69.360.920.1585490
2024-12-20INSM70.440.910.0185484
2024-12-23INSM70.540.853.2066485
2024-12-24INSM70.530.860.5967087
2024-12-26INSM70.720.850.4567887
2024-12-27INSM69.620.851.3968241
2024-12-30INSM68.850.850.0568505
2024-12-31INSM69.070.850.1168718
2025-01-02INSM69.960.840.8569284
2025-01-03INSM69.810.850.5469879
2025-01-06INSM66.620.860.1370396
2025-01-07INSM66.10.810.2973926
2025-01-08INSM65.750.810.8373981
2025-01-09INSM65.720.810.8073981
2025-01-10INSM65.310.820.1374556
2025-01-13INSM68.960.820.2874967
2025-01-14INSM68.30.800.2076262
2025-01-15INSM70.070.800.0476163
2025-01-16INSM72.770.800.0176366
2025-01-17INSM72.490.770.2378295
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19INSM69.407.4147.7-5.36
2024-12-20INSM70.487.4131.6-5.36
2024-12-23INSM70.597.4140.5-5.36
2024-12-24INSM70.537.4142.4-5.36
2024-12-26INSM70.677.4140.5-5.36
2024-12-27INSM69.637.4151.6-5.36
2024-12-30INSM68.907.4148.6-5.36
2024-12-31INSM69.047.4140.2-5.36
2025-01-02INSM69.987.4132.8-5.36
2025-01-03INSM69.817.4143.2-5.36
2025-01-06INSM66.647.4172.4-5.36
2025-01-07INSM66.107.4147.0-5.36
2025-01-08INSM65.727.4145.8-5.36
2025-01-09INSM65.727.4141.8-5.36
2025-01-10INSM65.267.4146.5-5.36
2025-01-13INSM68.967.4104.0-5.36
2025-01-14INSM68.247.4148.5-5.36
2025-01-15INSM70.207.4123.3-5.36
2025-01-16INSM72.747.4117.9-5.36
2025-01-17INSM72.467.4144.5-5.36
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19INSM-8.108.517.23
2024-12-20INSM-8.608.517.23
2024-12-23INSM-8.498.617.23
2024-12-24INSM-8.498.617.23
2024-12-26INSM-8.618.617.45
2024-12-27INSM-8.608.617.45
2024-12-30INSM-8.728.507.45
2024-12-31INSM-8.728.507.45
2025-01-02INSM-8.588.507.45
2025-01-03INSM-8.608.507.45
2025-01-06INSM-9.118.647.45
2025-01-07INSM-9.118.647.45
2025-01-08INSM-9.108.647.45
2025-01-09INSM-9.108.647.45
2025-01-10INSM-9.108.647.45
2025-01-13INSM-10.378.648.84
2025-01-14INSM-10.378.648.84
2025-01-15INSM-10.378.648.84
2025-01-16INSM-10.378.648.84
2025-01-17INSM-11.158.648.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.27

Avg. EPS Est. Current Quarter

-1.19

Avg. EPS Est. Next Quarter

-1.26

Insider Transactions

-11.15

Institutional Transactions

8.64

Beta

1.11

Average Sales Estimate Current Quarter

96

Average Sales Estimate Next Quarter

86

Fair Value

Quality Score

32

Growth Score

52

Sentiment Score

95

Actual DrawDown %

10

Max Drawdown 5-Year %

-63.3

Target Price

89.53

P/E

Forward P/E

PEG

P/S

37.82

P/B

26.83

P/Free Cash Flow

EPS

-5.56

Average EPS Est. Cur. Y​

-5.36

EPS Next Y. (Est.)

-4.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-252.01

Relative Volume

1

Return on Equity vs Sector %

-197.9

Return on Equity vs Industry %

-185.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

144.5
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 912
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading